Myocarditis: Diagnosis, Endomyocardial Biopsy, Cardiac MRI, and Treatment

Myocarditis: Diagnosis, Endomyocardial Biopsy, Cardiac MRI, and Treatment

Lake Louise CMR criteria, fulminant management, giant cell immunosuppression, and ICI myocarditis – a comprehensive evidence-based approach.

Executive Summary

Myocarditis is inflammation of the myocardium most commonly triggered by viruses (Coxsackie B, parvovirus B19, HHV-6, SARS-CoV-2), with autoimmune, drug-induced (immune checkpoint inhibitors), and idiopathic etiologies. Presentation ranges from asymptomatic ECG changes to fulminant cardiogenic shock and sudden cardiac death. The 2018 updated Lake Louise Criteria using cardiac MRI (T1 + T2 mapping plus LGE) provide noninvasive diagnosis with 88% sensitivity and 96% specificity. Endomyocardial biopsy remains the gold standard and is essential when giant cell, eosinophilic, sarcoid, or ICI-associated myocarditis is suspected because these specific etiologies require disease-altering immunosuppression. Fulminant myocarditis warrants early mechanical circulatory support (VA-ECMO threshold should be low) given that LV recovery exceeds 70% in survivors. Standard therapy includes guideline-directed heart failure medications and arrhythmia management, with strict exercise restriction for 3-6 months to mitigate exercise-induced sudden death risk during the inflammatory window.

10-22
Per 100,000 person-years (annual incidence)
88%
CMR sensitivity (Lake Louise 2018)
9-16%
Cause of sudden death in young athletes
40-50%
ICI myocarditis mortality
Table of Contents
  1. Etiology, Pathogenesis, and Clinical Spectrum
    • Viral, autoimmune, drug, ICI etiologies
    • Three clinicopathologic patterns
  2. Clinical Presentation and Initial Workup
    • Troponin, ECG, echocardiography
    • Differential from ACS, takotsubo
  3. Cardiac MRI and Lake Louise Criteria
    • 2018 updated criteria
    • T1/T2 mapping, LGE patterns
  4. Endomyocardial Biopsy: Indications and Yield
    • AHA/ESC Class I indications
    • Histologic subtypes (Dallas, lymphocytic, giant cell, eosinophilic)
  5. Treatment by Subtype
    • Standard supportive HF management
    • Fulminant: MCS strategy
    • Giant cell, eosinophilic, sarcoid, ICI immunosuppression
  6. Exercise Restriction, Follow-up, and Special Populations
    • Return-to-play criteria
    • Pregnancy, vaccine-associated, post-COVID

Section 1. Etiology, Pathogenesis, and Clinical Spectrum

Myocarditis is histologically defined as inflammatory infiltrates of the myocardium with myocyte necrosis or degeneration not characteristic of ischemic injury. Annual incidence is 10-22 per 100,000 person-years globally, with peaks in young adults (median age 20-50). Men are affected approximately 1.5-2x more often than women. The clinical importance of myocarditis is disproportionate to its prevalence because it accounts for 9-16% of sudden cardiac deaths in young athletes and 9-12% of cases of unexplained dilated cardiomyopathy.

Etiologic Classification

Etiologies are stratified by frequency and mechanism, with each carrying distinct prognostic and therapeutic implications.

CategorySpecific CausesFrequencyTreatment Implication
Viral (most common)Parvovirus B19, HHV-6, Coxsackie B, adenovirus, influenza A/B, SARS-CoV-2, EBV, CMV, HIV50-60%Supportive only; specific antivirals not routinely indicated
Bacterial/spirochetalBorrelia (Lyme), Corynebacterium diphtheriae, Mycoplasma, group A strep, Tropheryma whipplei5-10%Targeted antibiotics; pacemaker for Lyme AV block
ParasiticTrypanosoma cruzi (Chagas), Toxoplasma, TrichinellaEndemic regionsBenznidazole/nifurtimox (Chagas)
Autoimmune/systemicSarcoidosis, SLE, polymyositis/dermatomyositis, rheumatoid arthritis, eosinophilic granulomatosis with polyangiitis, IBD, celiac10-15%Disease-specific immunosuppression
Drug-inducedAnthracyclines, clozapine, mesalamine, sulfonamides, anti-TNF agents, smallpox vaccine5-10%Discontinuation; corticosteroids if hypersensitivity
Immune checkpoint inhibitorsPembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, cemiplimab1% of treatedPermanent ICI cessation + high-dose steroids + 2nd-line agents
Idiopathic giant cellUnknown trigger; T-cell mediatedRare (~0.1%)Triple immunosuppression; transplant evaluation
Eosinophilic (hypersensitivity, Loeffler)Drug hypersensitivity, parasitic, hypereosinophilic syndrome, EGPARareStop offending agent; corticosteroids
Cardiac sarcoidosisGranulomatous; isolated cardiac form possible5% of all myocarditisCorticosteroids + steroid-sparing agents; ICD threshold low
ToxicCocaine, methamphetamine, heavy metals (cobalt), envenomationVariableRemoval of toxin; supportive

Pathogenesis: Three-Phase Model

Viral myocarditis classically progresses through three pathobiologic phases that determine clinical course and the window of therapeutic opportunity.

  • Phase 1 – Acute viral injury (days 0-7): Direct viral replication causes myocyte injury through cytopathic effect. Innate immunity (NK cells, type I interferons) limits viral spread. This phase is often subclinical or mimics flu.
  • Phase 2 – Subacute immune phase (days 7-28): Adaptive immunity activates – cytotoxic CD8+ T cells, antibody responses, and macrophage infiltration. Most clinical presentations occur here. Inappropriate or sustained immune activation drives ongoing myocyte loss; this is where giant cell, eosinophilic, and ICI patterns emerge.
  • Phase 3 – Chronic phase (>28 days): Most patients clear virus and inflammation resolves. A subset (10-20%) develops persistent inflammation, viral genome persistence, or molecular mimicry-driven autoimmunity progressing to dilated cardiomyopathy. EMB-detectable viral genomes (parvovirus B19, HHV-6) in DCM are common but their prognostic significance is debated.
Viral Myocarditis Pathogenesis – Three Phases Acute viral injury, subacute immune phase, and chronic phase showing transition to dilated cardiomyopathy Phase 1 – Acute Viral Days 0-7 – Direct viral replication – Cytopathic myocyte injury – Innate immunity (NK, IFN) – Often subclinical/flu-like Therapy: supportive – Antivirals only if specific pathogen and within window Phase 2 – Subacute Days 7-28 – Adaptive immunity peaks – CD8+ T-cell cytotoxicity – Antibody, macrophage influx – Most clinical presentations Therapy: HF + arrhythmia – MCS for fulminant – Immunosuppression for giant cell, eosinophilic, sarcoid, ICI subtypes Phase 3 – Chronic Days >28 – 80-90% recover fully – 10-20% progress to DCM – Viral genome persistence – Molecular mimicry Therapy: long-term GDMT – Serial echo + CMR – ICD if persistent EF <35% – Transplant evaluation Adapted from ESC Position Statement on Myocarditis – therapeutic windows shift across phases

Three Clinicopathologic Patterns (Lieberman Classification)

The Lieberman classification, modified by Felker, defines four clinical patterns based on onset, hemodynamics, and histology that drive prognosis and therapy.

  • Fulminant myocarditis: Distinct viral prodrome, rapid HF onset (<2 weeks), severe LV dysfunction, often cardiogenic shock requiring inotropes/MCS, but normal-sized LV. Excellent long-term prognosis if patient survives the acute phase - most recover normal function within 6-12 months.
  • Acute myocarditis: Less distinct onset, mild-to-moderate LV dysfunction with dilated chamber, requires standard HF therapy. Variable course – 50% recover, 25% stable chronic LV dysfunction, 25% progressive HF/death/transplant.
  • Chronic active myocarditis: Insidious onset over months, moderate LV dysfunction with chronic inflammation, may have ventricular arrhythmias. Worse prognosis than fulminant.
  • Chronic persistent myocarditis: Persistent histologic inflammation without LV dysfunction, often with ongoing chest pain or palpitations, generally good prognosis.

Section 2. Clinical Presentation and Initial Workup

Myocarditis presents with three dominant phenotypes that often overlap. Recognition demands high clinical suspicion in young adults presenting with new chest pain, heart failure, or arrhythmia, particularly within 2-4 weeks of a viral illness.

Three Cardinal Presentations

  • Chest pain phenotype (50-60%): Mimics ACS with retrosternal chest pain, troponin elevation, ST elevations or T-wave inversions on ECG. Often follows viral prodrome (URI, GI symptoms) by 1-4 weeks. Distinguishing from STEMI requires acute coronary angiography in many patients due to overlap. Pericarditic features (pleuritic pain worse supine) suggest myopericarditis – check for friction rub.
  • Heart failure phenotype (20-30%): New dyspnea, orthopnea, peripheral edema, fatigue. May be acute (fulminant) or subacute. Echo shows reduced LVEF often with global hypokinesis (vs regional WMA in ischemic cause). Significant fraction (20-50%) has restrictive filling, mimicking restrictive cardiomyopathy.
  • Arrhythmia/conduction phenotype (10-20%): New atrial or ventricular arrhythmias, AV blocks (high-grade in giant cell or sarcoid), syncope, or aborted SCD. New high-grade AV block in a young patient should prompt suspicion for cardiac sarcoidosis or Lyme disease. Persistent unexplained ventricular arrhythmias warrant CMR and EMB consideration.

Initial Workup Bundle

TestFindingImplication
12-lead ECGSinus tachycardia, diffuse ST elevation (myopericarditis), T-wave inversions, low voltage, AV block, ventricular ectopyNonspecific; new high-grade AV block raises sarcoid/Lyme suspicion
High-sensitivity troponinElevated in 35-50% of acute myocarditis; persistently elevated for days-weeks (vs short-lived rise in MI)Marker of myocyte necrosis; serial measurement guides activity
BNP/NT-proBNPElevated proportional to HF severityRisk stratification; monitor response
CRP, ESRElevated in active inflammationNonspecific; useful for monitoring
CBC, differentialEosinophilia (>5% or absolute >500) raises eosinophilic/hypersensitivity myocarditisTriggers EMB consideration
Comprehensive metabolic panel, LFTsHepatic congestion in advanced HF; hepatocellular pattern in shockBaseline; transaminitis >1000 suggests shock liver
TSHRule out thyrotoxic cardiomyopathy mimicBaseline workup
EchocardiogramWall motion abnormalities, LVEF, RV function, pericardial effusion, valvular regurgitation, restrictive fillingFirst-line imaging; guides hemodynamic management
Coronary angiography (or CCTA)Excludes obstructive CAD when ACS is in differentialOften necessary; CCTA preferred if pretest probability low
Cardiac MRILake Louise criteria (T2-based + T1-based)Noninvasive diagnostic gold standard
Targeted infectious serologiesHIV, hepatitis B/C, Lyme (endemic), Coxsackie/parvovirus only if early acuteRoutine viral PCR not recommended
Autoimmune workupANA, ANCA, RF, anti-CCP, anti-Ro/La when systemic features presentTargeted, not screening
Endomyocardial biopsySelected high-risk presentations (see Section 4)Required for diagnosis of giant cell, eosinophilic, sarcoid, ICI subtypes
Differential Diagnosis Pearl

The chest pain + troponin + ECG changes triad in a young patient without atherosclerotic risk factors should always raise myocarditis. Other essential differentials: Takotsubo (apical ballooning, emotional/physical trigger, no LGE on CMR), vasospastic angina (transient ST changes, response to nitrates), MINOCA (myocardial infarction with non-obstructive coronary arteries – includes embolism, dissection, and microvascular dysfunction), cardiac sarcoidosis (granulomatous LGE patterns, RV involvement), and arrhythmogenic cardiomyopathy (RV fatty replacement on CMR, family history).

Hemodynamic Risk Stratification on Presentation

  • Low risk: Normal LVEF, no arrhythmia, mild troponin elevation, hemodynamically stable. Outpatient cardiology follow-up acceptable after initial inpatient observation 24-48h. Most chest-pain phenotype patients fall here.
  • Intermediate risk: LVEF 35-50%, or NSVT, or AV block
  • High risk (require ICU): LVEF <35%, cardiogenic shock, sustained VT/VF, complete heart block, syncope. Aggressive workup including emergent EMB; threshold for VA-ECMO should be low.

Section 3. Cardiac MRI and Lake Louise Criteria

Cardiac MRI has revolutionized noninvasive diagnosis of myocarditis. The 2018 updated Lake Louise Criteria incorporate quantitative T1 and T2 mapping in addition to traditional LGE imaging, achieving 88% sensitivity and 96% specificity in acute presentations. CMR also provides prognostic information through patterns and extent of late gadolinium enhancement.

2018 Updated Lake Louise Criteria

Diagnosis of myocardial inflammation requires at least one T2-based criterion AND at least one T1-based criterion. Each individual criterion alone provides supportive but not diagnostic evidence.

DomainCriterionWhat It Detects
T2-based (edema)(1) Regional or global increase of myocardial T2 relaxation time
OR
(2) Increased signal intensity in T2-weighted CMR images
Myocardial edema indicating active inflammation
T1-based (injury)(1) Regional or global increase of native (non-contrast) myocardial T1 relaxation time
OR
(2) Increased extracellular volume (ECV)
OR
(3) Late gadolinium enhancement (LGE) in nonischemic distribution
Myocardial injury, fibrosis, hyperemia, capillary leak
Supportive (not required)Pericardial effusion or pericardial LGE; LV systolic dysfunction with regional or global wall motion abnormalitiesConcomitant pericardial inflammation; functional impairment

LGE Patterns in Myocarditis

The location and pattern of LGE provide etiologic clues and carry prognostic implications. Unlike ischemic LGE (subendocardial-to-transmural in coronary distribution), myocarditis LGE typically spares the subendocardium.

LGE PatternLocationEtiology CluePrognosis
Subepicardial linearLateral free wall, often basal-mid LVMost common in viral myocarditis (parvovirus B19)Generally favorable
Mid-wall septalMid-wall, septum, anteroseptalHHV-6, autoimmune, post-inflammatory DCMSeptal LGE confers ~3x increased SCD risk
Patchy/multifocalMultiple noncontiguous foci, often involving RV insertion pointsCardiac sarcoidosis (especially with RV involvement and basal septal hypokinesis)High arrhythmia risk; threshold for ICD
Transmural or subendocardialCoronary distributionStrongly suggests ischemic – reconsider diagnosis or look for coronary embolismDifferent etiology
Diffuse subendocardial circumferentialEndocardial layerEosinophilic/Loeffler endocarditis with thrombusRisk of embolic events

Quantitative Mapping Cutoffs

Mapping cutoffs are vendor- and field-strength-dependent; use locally validated normative ranges. General benchmarks at 1.5T:

  • Native T1: Normal 950-1050 ms; myocarditis typically >1080 ms (>2 SD above local mean)
  • T2: Normal 45-50 ms; myocarditis typically >55 ms
  • ECV: Normal 25-28%; myocarditis typically >30%
CMR Timing and Pitfalls

CMR is highest yield within 2-3 weeks of symptom onset. Sensitivity drops to ~50% beyond 4-6 weeks because edema resolves first, leaving only LGE which becomes harder to date. False negatives occur in: chronic myocarditis (edema resolved), focal disease missed by sampling, severe LV dysfunction limiting image quality. False positives occur in: recent ablation, vigorous exercise (mild T2 elevation), any cause of myocardial injury (Takotsubo can mimic). Always interpret CMR in clinical context.

Prognostic Value of CMR

Beyond diagnosis, CMR independently stratifies risk. The presence and extent of LGE are the strongest CMR predictors of major adverse cardiovascular events.

  • LGE extent >17% of LV mass: 2-3x increased risk of all-cause mortality, ventricular arrhythmias, and HF hospitalization
  • Septal LGE: ~3x increased SCD risk independent of LVEF
  • Persistent LGE at 6 months: Marker of irreversible scar; correlates with sustained LV dysfunction
  • Combination of LGE + reduced LVEF: Strongest predictor; warrants consideration of primary prevention ICD per individualized risk assessment
Myocarditis — Procedure Steps Surgical stepper: Myocarditis — Procedure Steps Myocarditis — Procedure Steps 1 Diagnosis Cardiac MRI with Lake Louise criteria (T1, T2, ECV, LGE) — 80% sensitivity; troponin elevation; ECG 2 Supportive therapy Treat HF: ACE-I/ARB, BB, diuretics; IV inotropes (dobutamine) if LV dysfunction; restrict 3 Mechanical circulatory support For fulminant myocarditis with cardiogenic shock: IABP, Impella, VA-ECMO bridge to recovery 4 Immunosuppression Giant cell: prednisone 1 mg/kg + cyclosporine; cardiac sarcoid: prednisone + MTX/MMF; eosinophilic: 5 Arrhythmia management VT: amiodarone, lidocaine; AVOID Vaughan-Williams Ic; AV block: temporary pacing; consider ICD if pe 6 Long-term + transplant Recovery: 50% complete, 25% improved, 25% chronic; serial echo q3mo; transplant for end-stage
Myocarditis — Procedure Steps

Section 4. Endomyocardial Biopsy: Indications and Yield

Endomyocardial biopsy (EMB) remains the histologic gold standard for myocarditis diagnosis, but is underutilized due to perceived risk and sampling error. The 2007 AHA/ACC/ESC consensus and 2013 ESC Working Group statement provide evidence-based selection criteria. EMB is essential when a specific histologic diagnosis would change management – particularly giant cell myocarditis, eosinophilic myocarditis, and cardiac sarcoidosis.

AHA/ACC/ESC Class I Indications (EMB Strongly Recommended)

  • New-onset HF <2 weeks duration with hemodynamic compromise and normal-sized or dilated LV (Dallas-fulminant pattern): Distinguishes lymphocytic (favorable, supportive only) from giant cell or eosinophilic (require immunosuppression).
  • New-onset HF 2 weeks to 3 months with dilated LV plus (a) new-onset ventricular arrhythmias, OR (b) Mobitz II or higher AV block, OR (c) failure to respond to standard therapy within 1-2 weeks: Identifies giant cell, sarcoid, or autoimmune patterns requiring specific therapy.

Class IIa Indications (Reasonable to Perform)

  • HF >3 months with dilated LV and new-onset arrhythmias or AV block, or failure to respond to standard therapy
  • Suspected anthracycline cardiotoxicity unresponsive to therapy
  • Restrictive cardiomyopathy of unknown cause
  • Suspected cardiac amyloidosis where alternative diagnosis (extracardiac biopsy, technetium pyrophosphate scan) is non-diagnostic
  • Suspected ICI myocarditis where diagnosis remains uncertain after CMR

Procedure Technique and Yield

  • Approach: Right ventricular septum via internal jugular or femoral vein under fluoroscopic or echocardiographic guidance. Left ventricular biopsy reserved for predominantly LV disease or after non-diagnostic RV biopsy.
  • Number of samples: Minimum 5-10 fragments to optimize sensitivity given patchy distribution. Insufficient sampling is the leading cause of false negatives.
  • Sample handling: Light microscopy (formalin), electron microscopy if amyloid suspected (glutaraldehyde), molecular diagnostics for viral PCR (frozen), immunohistochemistry for inflammatory cell characterization.
  • Sensitivity: 35-50% for diffuse processes (lymphocytic), higher for focal granulomatous disease (cardiac sarcoidosis EMB sensitivity only 25-30% due to focal nature – electroanatomic mapping-guided biopsy improves yield).
  • Complications: Cardiac perforation/tamponade 0.4-0.6%, AV block 1%, arterial puncture 1-2%. Mortality <0.1% in experienced centers.

Histopathologic Subtypes

SubtypeKey HistologyClinical FeaturesTreatment
LymphocyticLymphocytic infiltrate (predominantly T cells) with myocyte necrosis (Dallas criteria)Most common; viral or post-viral; variable severityStandard supportive HF therapy; immunosuppression not routine
Giant cellMultinucleated giant cells, lymphocytes, eosinophils, myocyte necrosis WITHOUT granulomasRapidly progressive HF, refractory VT/VF, AV block in young/middle-aged adults; T-cell mediatedTriple immunosuppression: high-dose steroids + cyclosporine/tacrolimus + mycophenolate; transplant evaluation
EosinophilicDense eosinophilic infiltrate +/- myocyte necrosis +/- endocardial fibrosisDrug hypersensitivity (mesalamine, sulfa, anti-TNF), parasitic, hypereosinophilic syndrome, EGPAStop offending agent; corticosteroids 1 mg/kg/day; treat underlying eosinophilia
Granulomatous (sarcoid)Non-caseating granulomas, multinucleated giant cells, fibrosis (NOT acute necrosis)AV blocks, ventricular arrhythmias, HF, often with extracardiac sarcoidosis (lung, lymph node, skin)Corticosteroids 0.5-1 mg/kg/day with steroid-sparing agents; ICD threshold low
ICI-associatedDense lymphocytic infiltrate (CD8+ predominant) +/- myocyte necrosis; may resemble lymphocytic but immunohistochemistry shows checkpoint pathway markersWithin 6 weeks of first ICI dose; often with myositis/myasthenia overlapPermanent ICI cessation + high-dose steroids + 2nd-line agents (infliximab, abatacept, anti-thymocyte globulin)
Borderline myocarditisInflammatory infiltrate WITHOUT myocyte necrosisMild presentation; debated entitySupportive; serial CMR follow-up

Section 5. Treatment by Subtype

Treatment of myocarditis combines (1) standard guideline-directed heart failure and arrhythmia management for all patients, (2) mechanical circulatory support for fulminant presentations, and (3) subtype-specific immunosuppression for giant cell, eosinophilic, sarcoid, and ICI myocarditis. The goal is myocardial recovery while avoiding immunosuppression-related complications in self-limited viral disease.

Standard Supportive Heart Failure Management

All patients with myocarditis-associated LV dysfunction (LVEF <50%) should receive guideline-directed medical therapy (GDMT) tailored to symptoms and hemodynamics.

  • Beta-blockers: Metoprolol succinate 12.5-200 mg PO daily or Carvedilol 3.125-25 mg PO BID – start low and titrate. Avoid in acute decompensation until volume optimized.
  • RAAS inhibition: ACEi/ARB/ARNI – Sacubitril-valsartan 24/26-97/103 mg PO BID preferred over ACEi/ARB if tolerated
  • MRA: Spironolactone 12.5-50 mg PO daily or Eplerenone 25-50 mg PO daily
  • SGLT2 inhibitors: Dapagliflozin 10 mg PO daily or Empagliflozin 10 mg PO daily regardless of diabetes status
  • Loop diuretics: Furosemide IV/PO titrated to euvolemia
  • NSAIDs and colchicine: Generally avoided in myocarditis (concern for worsening LV dysfunction in animal models). Colchicine acceptable for myopericarditis with predominant pericardial features.

Fulminant Myocarditis: Aggressive MCS Strategy

Fulminant myocarditis requires ICU admission with arterial line, central venous access, continuous telemetry, and early consideration of mechanical circulatory support. Survivors have excellent long-term recovery, so the threshold for MCS should be low.

  • VA-ECMO: Preferred MCS for biventricular failure or refractory shock. Provides full cardiopulmonary support; allows myocardial rest. Activate cannulation team early – delays to support associate with worse outcomes.
  • Impella CP/5.0/5.5: LV unloading; useful for predominantly left-sided failure. Reduces afterload and wall stress.
  • IABP: Limited efficacy in profound shock but easy to deploy as bridge.
  • Inotropes: Dobutamine, milrinone, epinephrine bridge to MCS but avoid prolonged high-dose use (myocardial oxygen demand, arrhythmia risk).
  • Vasopressors: Norepinephrine first-line for vasoplegia; vasopressin add-on. Target MAP >65 mmHg.
  • Arrhythmia management: Aggressive treatment; lidocaine or amiodarone for VT (avoid in fulminant if possible due to negative inotropy); urgent transvenous pacing for high-grade AV block.
  • Outcome: ECMO survival to discharge ~70% with normal LV recovery in most. Prolonged ICU stay (median 14-21 days for ECMO patients) but excellent functional outcome.
When to Refer / Transfer

Transfer to a tertiary center with EMB capability and MCS programs (VA-ECMO, Impella, durable LVAD, transplant) when: (1) cardiogenic shock or hemodynamic instability, (2) refractory ventricular arrhythmias, (3) high-grade AV block requiring temporary pacing, (4) suspected giant cell or fulminant pattern, (5) LVEF <30% in acute presentation, (6) suspected ICI myocarditis (multidisciplinary cardio-oncology team). Early transfer (before deterioration) yields better outcomes than crash transfer in shock.

Subtype-Specific Immunosuppression

SubtypeInduction RegimenMaintenanceAdjunctive
Giant cellMethylprednisolone 1 g IV daily x 3 days then Prednisone 1 mg/kg/day + Cyclosporine (target 150-250 ng/mL) or Tacrolimus (5-15 ng/mL)Triple therapy x 12 months minimum, then individualized taper; Mycophenolate 1-1.5 g BID or Azathioprine 2-3 mg/kg/dayICD or LifeVest; transplant evaluation; muromonab or ATG for refractory; cardiac MRI surveillance
EosinophilicMethylprednisolone 1 g IV daily x 3 days if severe; otherwise Prednisone 1 mg/kg/dayTaper over 6-12 months based on eosinophil count and CMR; consider mepolizumab/benralizumab for relapsing hypereosinophiliaStop offending drug; treat parasitic infection if applicable; HES workup (FIP1L1-PDGFRA – imatinib responsive)
Cardiac sarcoidosisPrednisone 0.5-1 mg/kg/day (typical 30-40 mg) for 1-3 monthsSlow taper to maintenance 5-10 mg/day for 12-24 months; Methotrexate 10-20 mg/week or Mycophenolate 1-1.5 g BID as steroid-sparingFDG-PET to assess inflammation activity and response; ICD for documented arrhythmias or LVEF <35% per HRS criteria
ICI myocarditisMethylprednisolone 1 g IV daily x 3-5 days then Prednisone 1 mg/kg/daySlow taper over 4-6 weeks; do NOT resume ICISteroid-refractory: Infliximab 5 mg/kg, Abatacept 10 mg/kg, Mycophenolate 1 g BID, ATG 1.5 mg/kg; emerging: ruxolitinib, tofacitinib
Lymphocytic (viral)Generally NOT immunosuppressedN/AStandard HF management; persistent symptoms with CMR-active inflammation may benefit from immunosuppression in trials (TIMIC, IMAC studies)
Autoimmune (SLE, RA, IBD)Treat underlying disease aggressively per rheumatology/GIDisease-specificCorticosteroids + DMARDs; biologics for refractory cases

Specific Considerations: ICI Myocarditis

ICI myocarditis represents a unique therapeutic challenge requiring rapid diagnosis and aggressive multimodal management.

  • Recognition: Suspect in any ICI-treated patient with new troponin elevation, ECG changes, dyspnea, or arrhythmia, even if mild. Routine baseline troponin and ECG before each cycle increasingly recommended.
  • Severity grading (CTCAE/ESMO): Grade 1 (asymptomatic biomarker abnormality) – hold ICI, expedited cardiology; Grade 2 (mild symptoms) – hospitalize, IV steroids; Grade 3-4 (severe) – ICU + high-dose steroids + 2nd-line agents.
  • Triple jeopardy syndrome: Concomitant myositis (CK elevation, weakness) and myasthenia gravis (ptosis, dysphagia, respiratory failure) overlap occurs in 25% of ICI myocarditis and carries 60-70% mortality. Check CK, neuromuscular exam, NIF/FVC.
  • Permanent ICI discontinuation: Rechallenge associated with 40-50% recurrence rate; only consider in carefully selected cases with multidisciplinary input.
  • Emerging evidence for JAK inhibitors: Ruxolitinib and tofacitinib showing benefit in steroid-refractory cases by interrupting interferon-gamma signaling.

Pearl/Pitfall Pairs

Pearl: Early ECMO Saves Lives in Fulminant Myocarditis

Don’t wait for multi-organ failure. The classic teaching that fulminant myocarditis has excellent recovery applies primarily to patients who survive the acute phase – and survival depends on early MCS deployment. When LVEF is <25% with rising lactate or escalating inotrope/vasopressor needs, activate VA-ECMO cannulation. Survivors typically recover normal LV function within 6-12 months and have favorable long-term outcomes comparable to never-having-had myocarditis.

Pitfall: Treating Suspected ICI Myocarditis as Lymphocytic

The histology overlaps significantly, but ICI myocarditis behaves like rejection – it requires immediate aggressive immunosuppression, not just supportive care. Failure to recognize and treat with high-dose steroids within 24-48 hours of diagnosis is associated with 60-70% mortality. Always ask cancer treatment history in any new myocarditis presentation; permanent ICI cessation is non-negotiable.

Pearl: New AV Block in Young Patient = Rule Out Sarcoid + Lyme

Unexplained Mobitz II or third-degree AV block in a patient under age 60 is cardiac sarcoidosis until proven otherwise. The HRS expert consensus criteria include EMB-proven granulomas OR extracardiac biopsy + cardiac involvement on FDG-PET/CMR. In endemic Lyme regions (Northeast US, Europe), serology for Borrelia is mandatory because Lyme carditis resolves with appropriate antibiotic therapy and does not require permanent pacemaker.

Pitfall: Restarting Exercise Too Early After Recovery

The temptation to clear an athlete with normalized LVEF and resolved symptoms at 6-8 weeks is dangerous. Sudden cardiac death risk persists during the inflammatory window even when imaging looks reassuring. The 3-6 month restriction (from AHA/ACC and ESC) is based on observed SCD events occurring in athletes who returned at 8-12 weeks. Use cardiopulmonary exercise testing, Holter, and CMR (showing edema resolution) before clearance, not symptoms alone.

Section 6. Exercise Restriction, Follow-up, and Special Populations

Exercise Restriction Guidelines (AHA/ACC and ESC)

Restriction from competitive athletics and high-intensity recreational exercise is mandatory in the acute and subacute phases. The rationale is that exercise increases viral replication in animal models, exacerbates inflammation, and provokes ventricular arrhythmias during the vulnerable window of myocardial healing.

Time PeriodRestrictionAllowed Activity
Acute (0-3 months)Strict abstention from competitive athletics and high-intensity exercise (>5 METs)Light ADLs only; no recreational sports; no resistance training
Subacute (3-6 months)Continued restriction pending return-to-play evaluationLight aerobic activity (walking) acceptable; gradual resistance training under guidance
Recovery (>6 months)Conditional return after RTP evaluation; lifelong surveillanceFull activity if RTP criteria met

Return-to-Play (RTP) Evaluation

Five criteria must all be met before clearance to competitive athletics:

  1. Normal LV systolic function (LVEF >=55%) on transthoracic echocardiogram
  2. Absence of clinically relevant arrhythmias on 24-48 hour ambulatory ECG (no NSVT, no frequent PVCs >500/24h, no AV block)
  3. Normal cardiopulmonary exercise test (no exercise-induced arrhythmias, no significant ST changes, normal hemodynamic response)
  4. Normal serum biomarkers (troponin, BNP) at rest
  5. Cardiac MRI showing resolution of edema (T2 mapping normalized); residual LGE may be acceptable if no active inflammation

Long-term Follow-up

  • Months 1-3: Cardiology visit at 1 month with echo, ECG; consider repeat troponin if initially elevated
  • Months 3-6: Repeat echo, ECG, ambulatory monitoring; CMR at 3-6 months to document recovery and assess for chronic inflammation
  • Year 1: Annual cardiology visit with echo; lifestyle counseling; family screening if specific etiology (sarcoidosis, ARVC mimics)
  • Long-term: Annual or biennial follow-up; immediate evaluation for new symptoms (palpitations, presyncope, exertional dyspnea)
  • ICD considerations: Per HRS/HFSA guidelines for sarcoid myocarditis (low threshold), giant cell myocarditis (LifeVest acutely, ICD pre-transplant), and post-myocarditis DCM with persistent EF <35% after 3-6 months optimized GDMT

Special Populations

Vaccine-Associated Myocarditis (mRNA COVID-19)

Post-mRNA-vaccination myocarditis was identified during 2021 mass vaccination, with incidence highest in young males (16-29 years) after second dose of mRNA-1273 (Moderna) or BNT162b2 (Pfizer). Clinical course is typically mild with rapid resolution.

  • Incidence: 50-100 per million doses in highest-risk group (males 16-29 after dose 2); much lower in older adults
  • Onset: 2-7 days post-vaccination, typically chest pain with troponin elevation
  • Imaging: CMR shows typical inflammatory pattern but generally less severe LGE; LV function usually preserved
  • Course: >90% have complete clinical recovery within days-weeks; long-term outcome data favorable
  • Management: Standard myocarditis approach but typically does not require immunosuppression; NSAIDs for pericarditic features; hospitalization 1-3 days
  • Future vaccines: Current CDC guidance avoids mRNA boosters in individuals with prior vaccine-associated myocarditis until further data; alternative vaccines (protein-based) may be considered

Pregnancy

  • Peripartum cardiomyopathy vs myocarditis: Distinguish using CMR (PPCM lacks active inflammation; myocarditis has T2/edema)
  • ACEi/ARB/ARNI/MRA contraindicated: Use hydralazine + isosorbide dinitrate, beta-blockers (metoprolol/labetalol), digoxin if needed
  • Bromocriptine: Considered for severe peripartum cardiomyopathy; not for true myocarditis
  • Delivery planning: Multidisciplinary team; cesarean if hemodynamically unstable; epidural over general anesthesia
  • Future pregnancies: Counseled against if persistent LV dysfunction; risk of relapse high

Post-COVID Myocarditis

  • Acute COVID-19 myocarditis: Identified in ~2-5% of severe COVID cases; clinical management identical to other viral myocarditis
  • Long COVID cardiac involvement: Subclinical CMR abnormalities reported but clinical significance uncertain; routine screening of asymptomatic COVID-recovered patients NOT recommended
  • Athletes returning to play after COVID: Symptomatic athletes or those with cardiopulmonary symptoms warrant ECG, troponin, echo before RTP; CMR if abnormal

Pediatric Myocarditis

  • Multisystem inflammatory syndrome (MIS-C): Post-COVID hyperinflammatory syndrome with myocarditis; treated with IVIG 2 g/kg + corticosteroids; distinct from typical pediatric viral myocarditis
  • IVIG: Pediatric viral myocarditis benefits from IVIG 2 g/kg in some studies (unlike adult viral myocarditis); discuss with pediatric cardiology
  • VA-ECMO threshold: Even lower than adults given excellent recovery potential

Frequently Asked Questions

Section 7. Practice Insights: Cardiac MRI With Updated 2018 Lake Louise Criteria Is the Diagnostic Pivot

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Edema on cardiac MRI fades within weeks while late gadolinium enhancement persists, so a scan deferred in myocarditis loses half its answer — this disease is mismanaged not at the treatment step but at the diagnostic step: troponin-positive chest pain in a young patient without coronary disease is misdiagnosed as MINOCA without specific etiology, while myocarditis is treated as the assumed cause without confirmation, and immunosuppression is sometimes initiated empirically without biopsy. In experienced practice, the single most important question to ask after troponin-positive chest pain in a young patient with non-obstructed coronaries is: “Have we obtained cardiac MRI with the updated 2018 Lake Louise Criteria, and is endomyocardial biopsy indicated for the subtype?”

Cardiac MRI 2018 Lake Louise Criteria Application

The 2018 update of Lake Louise criteria requires at least 1 T2-based (T2 mapping or T2-weighted imaging showing edema) plus at least 1 T1-based (T1 mapping, ECV, or LGE) sequence positive for myocarditis diagnosis. This is more specific than the original 2009 criteria. In practice, experienced clinicians ensure both T2 mapping AND late gadolinium enhancement (LGE) imaging are performed — many centers still default to LGE-only protocols, which miss edema-predominant acute myocarditis. The mid-wall or subepicardial LGE pattern (sparing endocardium) is characteristic and distinguishes from ischemic injury (subendocardial). Seasoned clinicians refuse to commit to myocarditis diagnosis on troponin elevation alone.

Endomyocardial Biopsy — When Experienced Practitioners Insist On It

EMB indications in experienced practice are limited but absolute: new-onset heart failure under 2 weeks with hemodynamic compromise (suspect giant cell or fulminant lymphocytic), heart failure 2-4 weeks with new ventricular arrhythmias or AV block (suspect giant cell), heart failure with eosinophilia (suspect eosinophilic), suspected cardiac sarcoidosis (need histologic confirmation for granulomas), or suspected hypersensitivity myocarditis with recent drug exposure. For routine viral lymphocytic myocarditis, experienced clinicians do not pursue EMB — clinical course is supportive and biopsy adds risk without changing management. Giant cell and sarcoidosis change management dramatically — EMB is justified.

Exercise Restriction Counseling Seasoned Clinicians Insist On

For confirmed myocarditis, the exercise restriction protocol is: complete cessation from exercise for 3-6 months from symptom onset (3 months minimum, 6 months for athletes or severe disease), then graduated return based on re-imaging (CMR resolution of edema and LGE stability) and absence of arrhythmias on 24-hour Holter and exercise stress testing. Return-to-play criteria from AHA/ACC require: LV function normalized, no LGE on follow-up CMR, normal Holter, normal exercise stress. Premature return to high-intensity exercise has been associated with sudden death from VT/VF; this is not a soft recommendation.

Subtype-Specific Treatment Where Evidence Differs

Viral lymphocytic myocarditis: supportive care + GDMT for any HF component; immunosuppression NOT routine (no benefit in trials). Eosinophilic myocarditis: high-dose steroids (prednisone 1 mg/kg daily tapered) plus search for underlying cause (parasites, drugs, hypereosinophilic syndrome). Giant cell myocarditis: cyclosporine + steroids ± antithymocyte globulin; high mortality without immunosuppression. Cardiac sarcoidosis: prednisone 0.5-1 mg/kg + methotrexate or azathioprine maintenance; PET-guided dosing. Checkpoint inhibitor myocarditis: high-dose IV methylprednisolone 1 g daily × 3-5 days then PO taper; discontinue checkpoint inhibitor permanently; consider ATG/abatacept if steroid-refractory.

Illustrative Scenario — Giant Cell Caught by Biopsy After CMR Suggested Lymphocytic

A man in his late thirties presented with new-onset heart failure (EF 28%), VT runs on telemetry, and progressive new AV conduction block over 7 days. Initial troponin was 2.4, BNP 1820. Cardiac MRI at hour 24 showed extensive mid-wall LGE and edema on T2 mapping — fulfilling 2018 Lake Louise criteria. Many would have called this “viral lymphocytic myocarditis” based on imaging alone and initiated supportive care. However, the trajectory was concerning: arrhythmias plus rapidly progressive AV block in a young patient suggested giant cell myocarditis. The treating clinicians pushed for emergent endomyocardial biopsy on hospital day 2. Pathology returned: multinucleated giant cells with eosinophilic infiltrate — confirming giant cell myocarditis. He was started on cyclosporine + high-dose steroids + antithymocyte globulin within 12 hours of biopsy result. After 3 weeks of immunosuppression he was hemodynamically stabilized, evaluated for and listed for heart transplantation; he underwent successful OHT at 4 months. Without biopsy he would have died from delayed immunosuppression.

Takeaway: CMR confirms myocardial inflammation but cannot distinguish viral lymphocytic from giant cell from sarcoidosis. Young patient with HF + arrhythmias + AV block needs EMB urgently — giant cell myocarditis has unique management (cyclosporine + steroids + ATG) that radically alters survival. Empiric “viral myocarditis” without biopsy in this presentation is a missed diagnosis with mortality consequences.

the established Protocol Adjustments to Standard Myocarditis Management

  1. Cardiac MRI with 2018 Lake Louise (T2 + T1 sequences): Both T2 mapping AND LGE imaging — not LGE-only protocol. Mid-wall/subepicardial pattern characteristic. Refuse troponin-alone diagnosis.
  2. EMB urgently for high-suspicion subtypes: New HF <2 wk with hemodynamic compromise, HF + new arrhythmias/AV block, eosinophilia, suspected sarcoidosis, hypersensitivity with drug exposure. Do not pursue for routine viral lymphocytic.
  3. Subtype-directed treatment: Viral → supportive + GDMT; Eosinophilic → steroids; Giant cell → cyclo + steroids + ATG; Sarcoidosis → prednisone + MTX/AZA + PET-guided; ICI → high-dose methylpred + permanent ICI cessation.
  4. Exercise restriction 3-6 months from symptom onset: Complete cessation; return only with normalized LV function + no LGE on follow-up CMR + normal Holter + normal stress. Premature return associated with VT/VF sudden death.
Myocarditis: 2018 Lake Louise & Subtype-Directed Treatment Two-panel diagram: left panel diagnostic algorithm from troponin elevation through cardiac MRI 2018 Lake Louise criteria with both T2 and T1 sequences to endomyocardial biopsy indications; right panel subtype-specific treatment matrix for viral eosinophilic giant cell sarcoid and checkpoint inhibitor myocarditis 2018 Lake Louise CMR & Subtype-Directed Therapy Diagnostic Algorithm Troponin↑ + suspicious clinical context Young, post-viral, chest pain, HF, arrhythmia Exclude obstructive coronary disease Coronary angiography or CCTA in >35 years Normal coronaries → MINOCA workup Cardiac MRI 2018 Lake Louise Requires ≥1 T2-based (edema): • T2 mapping OR T2-weighted imaging PLUS ≥1 T1-based (injury): • T1 mapping OR ECV OR LGE LGE pattern recognition Mid-wall or subepicardial (sparing endocardium) Subendocardial → ischemic, not myocarditis EMB indications (urgent) • New HF <2 wk with hemodynamic compromise • HF + new arrhythmias / AV block • Eosinophilia, suspected sarcoid, hypersensitivity Subtype-Directed Treatment Viral Lymphocytic (most common) Supportive care + GDMT if HF No routine immunosuppression Eosinophilic Prednisone 1 mg/kg/d tapered over weeks Search for parasites, drugs, HES Giant Cell (high mortality without Tx) Cyclosporine + steroids + ATG Listed for transplant if EF <30% EMB-confirmed diagnosis required Cardiac Sarcoidosis Prednisone 0.5-1 mg/kg/d + MTX or AZA maintenance PET-CT guided dosing; ICD if EF <35% Checkpoint Inhibitor Myocarditis High-dose methylpred 1 g/d × 3-5d PERMANENT ICI discontinuation ATG/abatacept if steroid-refractory
What is the best initial diagnostic test for suspected myocarditis?

Cardiac MRI with the updated 2018 Lake Louise Criteria (LLC) is the noninvasive gold standard. Diagnosis requires one T2-based criterion (edema on T2-weighted imaging or elevated T2 mapping) plus one T1-based criterion (LGE in nonischemic distribution, elevated native T1, or elevated extracellular volume). Sensitivity 88%, specificity 96% in acute presentation. CMR should be performed within 2-3 weeks of symptom onset for highest yield. Echocardiography is performed first to assess LV function but cannot confirm diagnosis.

When is endomyocardial biopsy indicated?

AHA/ACC/ESC Class I indications: (1) new-onset HF <2 weeks with hemodynamic compromise and normal/dilated LV (Dallas-Fulminant), (2) new-onset HF 2 weeks-3 months with dilated LV plus high-grade AV block, ventricular arrhythmias, or failure to respond to standard therapy within 1-2 weeks. EMB is essential when giant cell, eosinophilic, or sarcoid myocarditis is suspected because these require specific immunosuppression. Sensitivity 35-50% (sampling error); right ventricular septal sampling with 5-10 biopsies recommended.

How is fulminant myocarditis managed?

Fulminant myocarditis presents with cardiogenic shock requiring inotropes/vasopressors within 2 weeks of viral prodrome. Management: (1) ICU admission with arterial line, central venous access, continuous telemetry; (2) early mechanical circulatory support (VA-ECMO preferred, Impella, IABP) – threshold should be low because recovery is common; (3) avoid prolonged high-dose inotropes; (4) urgent EMB to rule out giant cell/eosinophilic; (5) treat arrhythmias aggressively (avoid type IC and class III if possible). Survival to discharge with MCS exceeds 70%, and most survivors recover normal LV function within 6-12 months.

What treatment is required for giant cell myocarditis?

Giant cell myocarditis requires immediate combination immunosuppression: high-dose corticosteroids (methylprednisolone 1 g IV daily x 3 days, then prednisone 1 mg/kg) plus calcineurin inhibitor (cyclosporine target trough 150-250 ng/mL OR tacrolimus 5-15 ng/mL) plus often mycophenolate or azathioprine. Without immunosuppression, median survival is 3 months; with triple therapy, transplant-free survival exceeds 70% at 1 year. ICD or LifeVest is recommended due to high arrhythmic risk. Heart transplant evaluation should be initiated early.

How is immune checkpoint inhibitor myocarditis treated?

ICI myocarditis is rare (1%) but high-mortality (40-50%). Onset typically within 6 weeks of first dose. Management: (1) hold ICI permanently; (2) high-dose methylprednisolone 1 g IV daily x 3-5 days, then taper over 4-6 weeks; (3) for steroid-refractory: add infliximab 5 mg/kg, abatacept 10 mg/kg, mycophenolate, or anti-thymocyte globulin; (4) JAK inhibitor ruxolitinib emerging for refractory cases; (5) frequent troponin and ECG monitoring. Concomitant myositis and myasthenia gravis (overlap syndrome) carry the highest mortality and require prompt recognition.

What are the exercise restriction guidelines after myocarditis?

AHA/ACC and ESC recommend abstention from competitive athletics and high-intensity exercise for at least 3-6 months after diagnosis. Return-to-play requires: (1) normal LV function (LVEF >=55%) on echo, (2) absence of clinically relevant arrhythmias on 24-48 hour Holter, (3) normal cardiopulmonary exercise test, (4) normal serum troponin, (5) ideally CMR showing resolution of edema (LGE may persist and is acceptable if no edema). Athletes who never had ventricular dysfunction may return at 3 months; those with significant LV dysfunction require 6 months of restriction. Sudden cardiac death risk during exercise persists for months after the acute phase.

Is there a role for routine antiviral or IVIG therapy in viral myocarditis?

No – routine antiviral or IVIG therapy is not recommended for adult viral myocarditis based on current evidence. The ESETCID trial showed no benefit of immunosuppression for biopsy-proven enteroviral or adenoviral myocarditis. IVIG (2 g/kg) shows benefit only in pediatric viral myocarditis and certain adult subsets. Specific scenarios where antivirals may be considered: ganciclovir/valganciclovir for biopsy-proven CMV myocarditis, oseltamivir for influenza myocarditis presenting within 48 hours. Standard management remains supportive (HF therapy, arrhythmia control) plus disease-specific immunosuppression for giant cell, eosinophilic, sarcoid, or autoimmune subtypes.

↑

Leave a Reply

Your email address will not be published. Required fields are marked *